Trump signs order to reduce regulatory barriers to domestic pharmaceutical manufacturing -White House statement
- Trump order directs the U.S. FDA to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants
- directs the FDA to improve enforcement of active pharmaceutical ingredient source reporting by foreign drug producers and consider publicly displaying a list of facilities that do not comply
Trump says he’ll have an announcement next week related to cost of medicines.
